Journal article
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial
Abstract
BACKGROUND: Doxorubicin chemotherapy is associated with cardiomyopathy. Dexrazoxane reduces cardiac damage during treatment with doxorubicin in children with acute lymphoblastic leukaemia (ALL). We aimed to establish the long-term effect of dexrazoxane on the subclinical state of cardiac health in survivors of childhood high-risk ALL 5 years after completion of doxorubicin treatment.
METHODS: Between January, 1996, and September, 2000, children …
Authors
Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA
Journal
The Lancet Oncology, Vol. 11, No. 10, pp. 950–961
Publisher
Elsevier
Publication Date
October 2010
DOI
10.1016/s1470-2045(10)70204-7
ISSN
1470-2045
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAntibiotics, AntineoplasticBiomarkersCanadaCardiomyopathiesCardiovascular AgentsChildChild, PreschoolDisease-Free SurvivalDoxorubicinFemaleHumansKaplan-Meier EstimateMaleMyocardial ContractionPrecursor Cell Lymphoblastic Leukemia-LymphomaProspective StudiesPuerto RicoRazoxaneRisk AssessmentRisk FactorsSurvivorsTime FactorsTreatment OutcomeTroponin TUltrasonographyUnited StatesVentricular Function, LeftYoung Adult